The objective of this review is to explore the past work done on Cubosomes as drug delivery systems by factorial design. Cubosomes are Nanoparticulate systems made of amphiphilic lipids at a certain percentage, known as liquid crystals. They have tightly packed honeycomb structures twisted into 3D bilayers. Cubosomes can capture all categories of the lipophilic, hydrophilic, and amphiphilic substances irrespective of their affinity, by that they fit for delivering all range of drugs with ease. Many works in recent days are concentrating on Cubosomes for drug delivery, as it suits all ranges of drugs without much difficulty. Cubosomes acts as a carrier in drug delivery for a wide range of drugs and protects them from degradation issues like hydrolysis, oxidation, and others. Moreover, numerous studies have established the benefits of Cubosomes in nanotechnology, prolonged-release, and also enhanced bioavailability. This article reviews about the past work done on Cubosomes using factorial design. Additionally, many studies need to be performed for the optimization of Cubosomes for artificial cells, and biosensors, etc. Moreover, the rational design of Cubosomes for biomedical applications need to be developed. A widespread literature assessment revealed that many reviews and research attempts were made on Cubosomes, but no review article is still available in bringing the attempts made on Cubosomes by factorial design on a single platform. The factorial approach is used to optimize the formulation, which is acceptable and used in the current scenario in optimizing the formulations. So, the authors made widespread work by referring to peer-review journals, periodicals, magazines, and succeeded in bringing work done on Cubosomes in the last ten years by using factorial design. The study concludes and gives a quick reference to the young researchers to get literature on earlier successive attempts done on Cubosomes by factorial design.
For a long time, drug delivery systems (DDS) have been targeted to get expected results. With nanotechnology-based DDS, a wide assortment of flawless challenges can be tackled at present. Known as a nanosponge, a nanosponge is a modern division of material consisting of tiny particles that transmit only a few nanometers. The nano-formulations are highly effective for the delivery of low-solubility drugs. Many drugs with narrow therapeutic windows can benefit from improving water solubility. It has even been claimed they can be utilized to target and control delivery. In addition, huge amounts of money have been spent on developing new formulations of the DDS in recent times. Learn how nanosponges are prepared, its advantages, and its disadvantages. Resources were consulted to comprehend recent enhancements and patents in the domain. The ideal DDS has been developed by combining many different formulations; nano sponges are one of them. Analysts have examined them and found that they produce positive results and can improve the stability of poorly water-soluble drugs. The drug will be released at the precise target site when it reaches the body and sticks to the surface of the target site. As medication maximum action declines, it is more difficult to formulate impotent drugs. Considering this, nanosponges are organized and examined to determine whether they are problematic. Nanosponges in drug delivery can be characterized by their characteristics, preparation, factors, and applications. The article was written based on research articles about nanosponges. Data on nanosponges drug delivery systems from the past decade was collected using a factorial design. Study authors report that factor design plays an imperative role in optimizing drug dosage forms. Researchers will save time by reviewing the literature on nanosponges via factorial designs instead of searching for it.
The United States Food and Drug Administration (USFDA) is one of the main regulated agencies wherein the submission and approval of the new drugs is done. This review is based on the process of submission to the ANDA as per FDA norms as described in paragraph IV submission in Federal Food, Drug, and Cosmetic Act (FD and C Act). No drug would exist in the market until it gets accepted by regulatory authorities. The ANDA submission is for those firms seeking to copy branded drugs before running out of patents to get profit on them. A generic applicant must provide in its application a "certification" that a patent submitted to FDA by the brand-name drug's sponsor and scheduled in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). A Generic Product must meet the standards recognized by FDA in Reference listed drugs (RLD). This study concludes the process of ANDA submission to FDA and acts correlated to the submission in paragraph IV, the details of ANDA filling in the eCTD format and overview of the review process the checklist to the applicant.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.